Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 15;25(24):13446.
doi: 10.3390/ijms252413446.

Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases

Cencan Xing  1   2 , Hongyu Chen  1   2 , Wangyu Bi  1   2 , Tong Lei  2 , Zhongci Hang  1   2 , Hongwu Du  1   2
Affiliations
Review

Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases

Cencan Xing et al. Int J Mol Sci. .

Abstract

There is increasing interest in the potential therapeutic role of 5-HT (serotonin) in the treatment of neurodegenerative diseases, which are characterized by the progressive degeneration and death of nerve cells. 5-HT is a vital neurotransmitter that plays a central role in regulating mood, cognition, and various physiological processes in the body. Disruptions in the 5-HT system have been linked to several neurological and psychiatric disorders, making it an attractive target for therapeutic intervention. Although the exact causes of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are not fully understood, researchers believe that regulating the 5-HT system could help alleviate symptoms and potentially slow the progression of these diseases. Here, we delve into the potential of harnessing 5-HT as a therapeutic target for the treatment of neurodegenerative diseases. It is important to note that the current clinical drugs targeting 5-HT are still limited in the treatment of these complex diseases. Therefore, further research and clinical trials are needed to evaluate the feasibility and effectiveness of its clinical application.

Keywords: 5-HT; clinical trials; neurodegenerative diseases; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Summary of the therapeutic mechanisms of 5-HT in NDs. Red arrows, upregulation; green arrows, downregulation.
Figure 2
Figure 2
Function of the 5-HT receptor in NDs. Where “formula image” indicates that the activation of this receptor contributes to the recovery of the symptom; “formula image” indicates that inhibition of this receptor contributes to the recovery of the symptom.
See this image and copyright information in PMC

References

    1. Pentkowski N.S., Rogge-Obando K.K., Donaldson T.N., Bouquin S.J., Clark B.J. Anxiety and Alzheimer’s disease: Behavioral analysis and neural basis in rodent models of Alzheimer’s-related neuropathology. Neurosci. Biobehav. Rev. 2021;127:647–658. doi: 10.1016/j.neubiorev.2021.05.005. - DOI - PMC - PubMed
    1. Ray S., Agarwal P. Depression and Anxiety in Parkinson Disease. Clin. Geriatr. Med. 2020;36:93–104. doi: 10.1016/j.cger.2019.09.012. - DOI - PubMed
    1. Dale M., van Duijn E. Anxiety in Huntington’s Disease. J. Neuropsychiatry Clin. Neurosci. 2015;27:262–271. doi: 10.1176/appi.neuropsych.14100265. - DOI - PubMed
    1. Liu Z., Zhou T., Ziegler A.C., Dimitrion P., Zuo L. Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. Oxid. Med. Cell. Longev. 2017;2017:2525967. doi: 10.1155/2017/2525967. - DOI - PMC - PubMed
    1. Khachaturian Z.S. Hypothesis on the regulation of cytosol calcium concentration and the aging brain. Neurobiol. Aging. 1987;8:345–346. doi: 10.1016/0197-4580(87)90073-X. - DOI - PubMed

MeSH terms

LinkOut - more resources